For Healthcare
Professionals
 

Indications & Usage


Ganite® is indicated for the treatment of clearly symptomatic cancer-related hypercalcemia that has not responded to adequate hydration. In general, patients with a serum calcium concentration (corrected for albumin) < 12 mg/dL would not be expected to be symptomatic.

Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without diuretics). In the treatment of cancer-related hypercalcemia, it is important first to establish adequate hydration, preferably with IV saline, in order to increase the renal excretion of calcium and correct dehydration caused by hypercalcemia.

Clinical Safety Considerations


WARNING: Concurrent use of gallium nitrate with other potentially nephrotoxic drugs (e.g.,aminoglycosides, amphotericin B) may increase the risk for developing severe renal insufficiency in patients with cancer-related hypercalcemia. If use of a potentially nephrotoxic drug is indicated during gallium nitrate therapy, gallium nitrate administration should be discontinued and it is recommended that hydration be continued for several days after administration of the potentially nephrotoxic drug. Serum creatinine and urine output should be closely monitored during and subsequent to this period. Ganite therapy should be discontinued if the serum creatinine level exceeds 2.5 mg/dL.

Please see Full Prescribing Information, including Boxed WARNING, WARNINGS and PRECAUTIONS.

  • Ganite should not be administered to patients with severe renal impairment (serum creatinine > 2.5 mg/dL)


  • Avoid overhydration in patients with compromised cardiovascular status


  • Diuretic therapy should not be employed prior to correction of hypovolemia


  • If hypocalcemia occurs, Ganite therapy should be stopped and short-term calcium therapy may be necessary

Please see Full Prescribing Information, including Boxed WARNING, WARNINGS and PRECAUTIONS.
© MMVI Genta Inc. All Rights Reserved